$0.12
-0.02 (-15.69%)
Open$0.15
Previous Close$0.14
Day High$0.15
Day Low$0.10
52W High$7.34
52W Low$0.09
Volume—
Avg Volume48.1K
Market Cap1.42M
P/E Ratio—
EPS$-9.39
SectorBiotechnology
Analyst Ratings
Strong Sell
8 analysts
Price Target
+29,350.8% upside
Current
$0.12
$0.12
Target
$35.93
$35.93
$28.98
$35.93 avg
$50.96
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 2.73M | 1.55M | 1.36M |
| Net Income | -107,722,981 | 56.6K | 59.8K |
| Profit Margin | -3,951.9% | 3.7% | 4.4% |
| EBITDA | -144,097,850 | 150.2K | 130.3K |
| Free Cash Flow | — | 63.5K | 61.7K |
| Rev Growth | — | -6.9% | +10.8% |
| Debt/Equity | — | 0.70 | 0.59 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $294.45 | -0.18% | 49.3 | 509.50B |
| AMGN | Amgen Inc | $467.06 | -0.22% | 26.5 | 248.84B |
| GILD | Gilead Sciences Inc | $167.95 | -1.05% | — | 208.28B |
| VRTX | Vertex Pharmaceuticals Inc | $542.62 | -0.81% | 34.5 | 137.12B |
| REGN | Regeneron Pharmaceuticals | $951.19 | -0.86% | 19.4 | 93.39B |
| ALNY | Alnylam Pharmaceuticals Inc | $156.65 | -2.00% | 7.7 | 20.98B |